Navigation Links
MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
Date:11/12/2008

MOUNTAIN VIEW, Calif., Nov. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2008.

The net loss for the third quarter ended September 30, 2008 was $20.4 million compared with $9.8 million during the same period in 2007. The net loss for the nine months ended September 30, 2008 was $51.1 million compared to $25.2 million for the nine months ended September 30, 2007. As of September 30, 2008, MAP Pharmaceuticals had cash, cash equivalents and short-term investments of $63.0 million.

"We had a very busy and productive third quarter with two active Phase 3 clinical programs ongoing. We completed patient enrollment of our Phase 3 trial of Unit Dose Budesonide, or UDB, for the potential treatment of pediatric asthma, and continued enrollment of our Phase 3 trial of MAP0004 for the potential treatment of migraine," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "In this environment, we continue to manage our resources prudently as we advance toward our goal of commercializing clearly differentiated products that address major market opportunities."

Third Quarter 2008 and Recent Accomplishments

Clinical development

-- UDB: Completed enrollment and randomized approximately 360 patients in a Phase 3 clinical trial to evaluate UDB for the potential treatment of pediatric asthma. The last patient in this trial is expected to complete the 12-week treatment period by the end of 2008.

-- MAP0004: Initiated enrollment in a Phase 3 clinical trial to evaluate MAP0004 for the potential treatment of migraine, pursuant to a Special Protocol Assessment with the U.S. Food and Drug Administration.

Other corporate progress

-- Added industry veterans to the management team and board of directors, including: Donald J. Kellerman, Pharm.D. to the position of Senior Vice President, Clinical Development and Medical Affairs; Alan H. Cohen, M.D., to the position of Vice President, Clinical Development and Medical Affairs, Pulmonary; and Scott R. Ward to the board of directors.

-- Published positive results in a scientific journal from a Phase 2 study evaluating the safety, tolerability and pharmacokinetics of MAP0004 in adult asthmatics, and presented three posters related to MAP0004 at the European Headache and Migraine Trust International Congress.

Third Quarter and Nine Month Financial Results

Research and development expenses for the three and nine months ended September 30, 2008 were $16.8 million and $41.6 million, respectively, compared to $7.5 million and $18.3 million, respectively, for the same periods in 2007. The increase in research and development expenses for the three and nine months ended September 30, 2008 as compared to the same periods in 2007 was primarily driven by an increase in clinical expenses to support Phase 3 clinical programs initiated in 2008 for our two lead product candidates, UDB and MAP0004, and an increase in personnel related expenses and stock-based compensation in support of these clinical programs.

Sales, general and administrative expenses for the three and nine months ended September 30, 2008 were $3.4 million and $9.7 million, respectively, compared to $2.4 million and $6.8 million, respectively, for the same periods in 2007. The increase in sales, general and administrative expenses for the three months ended September 30, 2008 as compared to the same period in 2007 was primarily related to increases in personnel related expenses and stock-based compensation, as well as increases due to professional fees, outside services and other administrative related costs. The increase in sales, general and administrative expenses for the nine months ended September 30, 2008 as compared to the same period in 2007 was primarily related to increases in personnel related expenses and stock-based compensation, as well as increases due to professional fees, outside services and other administrative related costs, partially offset by a decrease in non-recurring IPO expenses incurred in the prior year.

MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of September 30, 2008 of $63.0 million, compared to $95.0 million as of December 31, 2007. In addition, for the three and nine months ended September 30, 2008, non-cash share-based compensation and depreciation was approximately $1.5 million and $4.0 million, respectively.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' late stage clinical programs. Actual results may differ materially from current expectations based on risks and uncertainties affecting MAP Pharmaceuticals' business, including, without limitation, risks and uncertainties relating to the enrollment and conduct of clinical trials, as well as risks related to the failure to achieve favorable clinical outcomes and that MAP Pharmaceuticals' product candidates will not be approved for commercial use by the U.S. Food and Drug Administration. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on August 13, 2008, and available at http://edgar.sec.gov .

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

September 30, December 31,

2008 2007

Assets

Current assets:

Cash, cash equivalents and short-term

investments $63,021 $94,990

Other current assets 525 1,079

Total current assets 63,546 96,069

Property and equipment, net 4,927 4,183

Restricted cash 310 321

Other assets 27 122

Total assets $68,810 $100,695

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued expenses $14,360 $8,912

Current portion of long-term debt 4,725 3,820

Total current liabilities 19,085 12,732

Long-term debt, less current portion 15,827 6,357

Other liabilities 41 -

Total liabilities 34,953 19,089

Total stockholders' equity 33,857 81,606

Total liabilities and stockholders' equity $68,810 $100,695

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Operating expenses:

Research and

development $16,815 $7,510 $41,614 $18,343

Sales, general and

administrative 3,380 2,366 9,685 6,823

Total operating expenses 20,195 9,876 51,299 25,166

Loss from operations (20,195) (9,876) (51,299) (25,166)

Other income (expense), net (168) 34 179 (24)

Net loss (20,363) (9,842) (51,120) (25,190)

Cumulative stock

dividend attributable

to preferred

stockholders

- (1,902) - (5,575)

Net loss attributable to

common stockholders $(20,363) $(11,744) $(51,120) $(30,765)

Net loss per share

attributable to common

stockholders, basic and

diluted

$(1.00) $(14.07) $(2.52) $(39.27)

Weighted-average common

shares used in computing

net loss per share

attributable to common

stockholders, basic and

diluted 20,398,682 834,433 20,308,206 783,379


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
2. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
3. Jazz Pharmaceuticals, Inc. to Announce Third Quarter Financial Results on November 13, 2008
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
5. MAP Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
6. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
7. Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
8. Memory Pharmaceuticals Announces Six Abstracts Accepted for Presentation at Society for Neuroscience Meeting
9. Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
11. Sagent Pharmaceuticals Announces Presentations at Upcoming Lazard Capital Markets and Piper Jaffray Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... The threat ... went to work for a company involved in the underground testing of nuclear weapons. ... “Dying for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... on laser diffraction analysis as a tool to characterize particle size distributions in ... to obtain improved results and novel scientific findings. It describes methods of optimized ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail electric company ... Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , Discount Power ... customers and 2,250 RCEs at the time of acquisition. In the three years ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... clinic serving San Francisco and environs, is proud to announce an upgrade to ... information on the upgraded Yelp page on topics as diverse as Platelet Rich ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, ... the 7th Edition of International Social Design Awards. , The 7th A' ... System Designers, Governments and Institutions worldwide with realized projects and conceptual works. , ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017   Royal Philips ... global leader in health technology, today announced 510(k) ... (FDA) to market its ElastQ Imaging capability, further ... ultrasound systems. ElastQ Imaging enables simultaneous imaging of ... essential for the diagnosis of various liver conditions. ...
(Date:2/27/2017)... , Feb. 27, 2017  Infinity Pharmaceuticals, Inc. ... the Cowen and Company 37 th Annual Healthcare ... ET in Boston, MA. A ... the Investors/Media section of Infinity,s website at www.infi.com ... the event. About Infinity,Infinity is an innovative ...
(Date:2/27/2017)... 27, 2017 A recent research report published ... market alone is expected to reach a value of $55.8 billion ... along with 28 states have legalized marijuana for medical uses. In ... Florida , North Dakota , ... to use the drug in medical applications such as chemotherapies and ...
Breaking Medicine Technology: